

Symtuza® (darunavir/cobicistat/emtricitabine/tenofovir) – Expanded indication

- On March 2, 2020, the <u>FDA approved</u> Janssen's <u>Symtuza</u> (<u>darunavir/cobicistat/emtricitabine/tenofovir</u>), as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 40 kg: who have no prior antiretroviral treatment history or who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months and have no known substitutions associated with resistance to darunavir or tenofovir.
 - Symtuza was previously approved for this indication in adults only.
- The pharmacokinetic profile, safety, and antiviral activity of the components of Symtuza were evaluated in open-label clinical studies in pediatric patients.
 - In one study, darunavir and cobicistat once daily with two nucleoside reverse transcriptase inhibitors (NRTIs) were evaluated in 7 virologically suppressed pediatric patients aged 12 to less than 18 years and weighing at least 40 kg. At week 48, the proportion of patients who maintained HIV-1 RNA < 50 copies/mL was 86%, and the median change in CD4+ cell count from baseline was -342 cells/mm³ (range -1,389 to 210 cells/mm³).</p>
 - In a second study, cobicistat, emtricitabine, and tenofovir alafenamide, as part of a fixed-dose combination regimen together with elvitegravir, were evaluated in 50 treatment-naïve pediatric patients with HIV-1 aged 12 to less than 18 years and weighing at least 35 kg. At week 48, the proportion of patients who had HIV-1 RNA < 50 copies/mL was 92%, and the median increase in CD4+ cell count from baseline was 220 cells/mm³.</p>
- Symtuza carries a boxed warning for post treatment acute exacerbation of hepatitis B.
- The most common adverse reactions (≥ 2%) with Symtuza use were diarrhea, rash, nausea, fatigue, headache, abdominal discomfort, and flatulence.
- The recommended dosage of Symtuza is one tablet taken orally once daily with food in adults and pediatric patients weighing at least 40 kg.
- Symtuza is a four-drug fixed dose combination product containing 800 mg of darunavir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamide.



optumrx.com

OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.